CHILDRENS NATIONAL MEDICAL CENTER

国家儿童医疗中心

• 批准号: 6633403
• 负责人: Roger Packer
• 金额: $ 13.14万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-04-01 至 2005-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6633403
• 关键词: antineoplastics; blood brain barrier; brain neoplasms; central nervous system neoplasms; child (0-11); clinical research; clinical trial phase I; clinical trial phase II; clinical trial phase III; cooperative study; gene therapy; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer therapy; patient oriented research; pediatric neoplasm /cancer; quality of life

As a member of the Pediatric Brain Tumor Clinical Trials Consortium, the CNMC Neuro-Oncology Program proposes to develop, facilitate, and participate in innovative hypothesis-driven, technically challenging, clinical research designed to improve the survival and quality of life of children with primary central nervous system tumors. It is anticipated that these investigations will include, but will not be limited to: the use of novel chemotherapeutic agents; means to overcome the blood-brain barrier, immunotherapeutic approaches; modifications of radiation therapy; and new neurobiologic approaches, such as gene therapy, maturation agents, and anti-angiogenesis agents. The CNMC Neuro-Oncology Program plans on participating in research investigations which will improve the means to diagnose and characterize childhood brain tumors and to develop and participate in carefully monitored innovative diagnostic and therapeutic studies which will lead to future Phase III studies for children with such tumors. Over the past five years, the CNMC Neuro-Oncology Program has evaluated and managed 442 children (new to the institution) with primary central nervous system tumors and has entered over 189 children on Phase I, Phase II, and Phase III clinical investigations. Investigations have been done over this period of time, in concert with private industry and working groups, evaluating novel approaches such as gene therapy, immunotherapy, and approaches to overcome the blood-brain barrier; as well as evaluations of new chemotherapeutic agents, intensification of chemotherapy, and means to increase the efficacy of radiotherapy. The CNMC Neuro-Oncology Program has a well-developed multidisciplinary clinical core which includes a weekly neuro-oncology clinic, a quarterly groupwide neuro- oncology planning meeting, and a regional referral system. The program has a well-designed data management system, and an established system for specimen accrual. State-of-the-art neuroradiologic, neuropathologic, neurosurgical and radiation-oncologic facilities are available. In addition, innovative neurobiologic investigations in childhood brain tumors have been successfully completed and are underway at CNMC. The well-developed program structure, expertise of the CNMC Neuro-Oncology Program, proven commitment to performance of clinical trials, and available facilities should ensure the ability of the CNMC Neuro-Oncology Program to effectively participate in the proposed Pediatric Brain Tumor Clinical Consortium.

作为小儿脑肿瘤临床试验联盟的成员， CNMC神经肿瘤学计划提议开发，促进和 参加创新的假设驱动的，技术挑战， 临床研究旨在改善生活的生存和质量 患有原发性中枢神经系统肿瘤的儿童。 这是 预计这些调查将包括，但不会 限制为：新型化学治疗剂的使用；手段克服 血脑屏障，免疫治疗方法；修改 放射治疗;和新的神经生物学方法，例如基因 治疗，成熟剂和抗血管生成剂。 CNMC 神经肿瘤学计划参与研究调查 这将改善诊断和表征童年的手段 脑肿瘤并开发和参与经过精心监测的 创新的诊断和治疗研究将导致未来 对患有此类肿瘤的儿童的III期研究。 在过去的五个 多年来，CNMC神经肿瘤学计划已评估和管理442 儿童（机构新手）与原发性中枢神经系统 肿瘤并已在I期，II期和相的189多名儿童中输入 III临床研究。 对此进行了调查 一段时间，与私营企业和工作组共同 评估新方法，例如基因疗法，免疫疗法和 克服血脑屏障的方法；以及评估 新的化学治疗剂，化学疗法的加强和 增加放疗的功效。 CNMC神经肿瘤学 计划具有完善的多学科临床核心 包括每周一次的神经肿瘤诊所 肿瘤计划会议和区域推荐系统。 该程序 具有精心设计的数据管理系统，并且已建立的系统 用于标本应计。 最先进的神经放射学 神经病理学，神经外科和辐射良性设施是 可用的。 此外，创新的神经生物学研究 儿童脑肿瘤已成功完成并正在进行中 在CNMC。 发达的计划结构，CNMC的专业知识 神经肿瘤学计划，对临床表现的良好承诺 试验和可用设施应确保CNMC的能力 有效参与拟议的神经肿瘤学计划 小儿脑肿瘤临床财团。